These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3802380)
1. Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer. Rosenblum MG; Hortobagyi GN Cancer Chemother Pharmacol; 1986; 18(3):247-51. PubMed ID: 3802380 [TBL] [Abstract][Full Text] [Related]
2. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Ajani JA; Hortobagyi GN; Frye D; Levin B; Boman BM; Faintuch JS Am J Clin Oncol; 1987 Apr; 10(2):139-40. PubMed ID: 3551577 [TBL] [Abstract][Full Text] [Related]
3. High-performance liquid chromatographic method for the quantitative analysis of a synthetic copolymer with antitumor activity (copovithane) and methylamine in human blood plasma and urine. Wingender W J Chromatogr; 1983 Apr; 273(2):319-26. PubMed ID: 6863446 [TBL] [Abstract][Full Text] [Related]
5. Clinical trial of high doses of Bay I 7433 (Copovithane). Ucci G; Riccardi A; Danova M; Faravelli M; Salvini P; Girino M Drugs Exp Clin Res; 1986; 12(8):713-5. PubMed ID: 3530678 [TBL] [Abstract][Full Text] [Related]
6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Amonafide in dogs. Lu K; McLean MA; Vestal ML; Newman RA Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Malspeis L; Grever MR; Staubus AE; Young D Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279 [TBL] [Abstract][Full Text] [Related]
9. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Chabot GG; Flaherty LE; Valdivieso M; Baker LH Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2). Rosenblum MG; Rios AM; Hersh EM Cancer Chemother Pharmacol; 1986; 18(3):243-6. PubMed ID: 3802379 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. Foster BJ; Wiegand RA; LoRusso PM; Baker LH Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Thompson P; Balis F; Serabe BM; Berg S; Adamson P; Klenke R; Aiken A; Packer R; Murry DJ; Jakacki R; Blaney SM Cancer Chemother Pharmacol; 2003 Nov; 52(5):417-23. PubMed ID: 12879279 [TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacological study of merbarone. Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205 [TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048 [TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Supko JG; Balcerzak SP; Kraut EH Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]